Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Our study evaluates the use of Laser-Assisted Immunotherapy (LIT) plus placebo and LIT plus
low-dose cyclophosphamide versus that of Standard of Care in patients presenting with Stage
IIIA, IIIB or IV breast cancer.
One-third of enrolled patients will receive LIT plus placebo, one-third will receive LIT plus
low-dose cyclophosphamide, and one-third will be assigned to a control group that receives
Standard of Care.